2 commercial payer policies list K50. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
2 policies from 1 payer
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of K50 |
|---|---|---|
| Entyvio (Vedolizumab) | Aug 1, 2026 | Covered |
| Skyrizi (Risankizumab-Rzaa) | Aug 1, 2026 | Covered |